UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetologia, 2012-06, Vol.55 (6), p.1577-1596

2012

Volltextzugriff (PDF)

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

Diabetologia, 2009, Vol.52 (1), p.17-30

2009

Volltextzugriff (PDF)

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy : A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

Diabetologia, 2006-08, Vol.49 (8), p.1711-1721

2006

Volltextzugriff (PDF)

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial

Diabetic medicine, 2013-11, Vol.30 (11), p.1293-1297

2013

Volltextzugriff (PDF)

Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study

Diabetes, obesity & metabolism, 2014-12, Vol.16 (12), p.1247-1256

2014

Volltextzugriff (PDF)

Is insulin the most effective injectable antihyperglycaemic therapy?

Diabetes, obesity & metabolism, 2015-02, Vol.17 (2), p.145-151

2015

Volltextzugriff (PDF)

Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study

Diabetic medicine, 2011-06, Vol.28 (6), p.715-723

2011

Volltextzugriff (PDF)

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial

Diabetes, obesity & metabolism, 2015-10, Vol.17 (10), p.965-973

2015

Volltextzugriff (PDF)

dead heat: target normal glucose levels in the intensive care unit--but with caution

Diabetologia, 2008-06, Vol.51 (6), p.909-910

Buse, J. B

2008

Volltextzugriff (PDF)

The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2004-03, Vol.6 (2), p.133-156

2004

Volltextzugriff (PDF)

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

BMJ, 2010-01, Vol.340 (jan08 1), p.b4909-b4909

2010

Volltextzugriff (PDF)

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial

Diabetic medicine, 2013-11, Vol.30 (11), p.1293

2013

Volltextzugriff (PDF)

Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11–14 year olds: The HEALTHY Study

International Journal of Obesity, 2016-07, Vol.40 (7), p.1157-1163

2016

Volltextzugriff (PDF)

Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome

Diabetes care, 2018-08, Vol.41 (8), p.1792-1800

2018

Volltextzugriff (PDF)

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: Update regarding the thiazolidinediones

Diabetologia, 2008-01, Vol.51 (1), p.8-11

2008

Volltextzugriff (PDF)

Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes

Diabetes, obesity & metabolism, 2016-01, Vol.18 (1), p.40-48

2016

Volltextzugriff (PDF)

Homeostasis Model Assessment of Insulin Resistance and Survival in Patients with Diabetes and Acute Coronary Syndrome

The journal of clinical endocrinology and metabolism, 2018-07, Vol.103 (7), p.2522-2533

2018

Volltextzugriff (PDF)

Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues

The Journal of biological chemistry, 1989-05, Vol.264 (14), p.7776-7779

1989

Volltextzugriff (PDF)

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations

Diabetes, obesity & metabolism, 2015-05, Vol.17 (5), p.477-486

2015

Volltextzugriff (PDF)

Molecular biology of mammalian glucose transporters

Diabetes care, 1990-03, Vol.13 (3), p.198-208

1990

Volltextzugriff (PDF)

Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes

Diabetes, obesity & metabolism, 2014-11, Vol.16 (11), p.1065-1069

2014

Volltextzugriff (PDF)

Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials

Diabetes, obesity & metabolism, 2015-05, Vol.17 (5), p.505-510

2015

Volltextzugriff (PDF)

Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials

Diabetes, obesity & metabolism, 2015-06, Vol.17 (6), p.560-565

2015

Volltextzugriff (PDF)

Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy

Diabetes, obesity & metabolism, 2014-03, Vol.16 (3), p.206-214

2014

Volltextzugriff (PDF)

1 – 25 von 519

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(453)
Mit Volltextzugriff
(420)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(346)
Life Sciences & Biomedicine
(326)
Humans
(272)
Male
(169)
Female
(160)
Diabetes
(148)
Endocrinology & Metabolism
(129)
Middle Aged
(128)
Diabetes Mellitus, Type 2 - Drug Therapy
(99)
Aged
(90)
Diabetes Mellitus
(81)
Adult
(79)
Biological And Medical Sciences
(77)
Risk Factors
(77)
Hypoglycemic Agents - Therapeutic Use
(75)
Medical Sciences
(65)
Neurosciences & Neurology
(60)
Clinical Trials
(59)
Clinical Neurology
(56)
Cardiovascular Disease
(52)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Diabetes Care
(56)
Headache
(31)
The New England Journal Of Medicine
(25)
Diabetes, Obesity & Metabolism
(24)
Diabetes
(23)
Neurology
(23)
Diabetologia
(19)
New England Journal Of Medicine
(14)
New England Journal Of Medicine/the new England Journal Of Medicine
(13)
Cephalalgia
(11)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy : A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial

Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study

Is insulin the most effective injectable antihyperglycaemic therapy?

Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial

dead heat: target normal glucose levels in the intensive care unit--but with caution

The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial

Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11–14 year olds: The HEALTHY Study

Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: Update regarding the thiazolidinediones

Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes

Homeostasis Model Assessment of Insulin Resistance and Survival in Patients with Diabetes and Acute Coronary Syndrome

Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations

Molecular biology of mammalian glucose transporters

Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes

Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials

Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19

Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy

Suchergebnisse filtern